Erythropoietin and Erythropoietin Receptor Levels and Their Diagnostic Values in Drug-naïve Patients with Generalized Anxiety Disorder

키워드

참고문헌 (48)

1. Maron E, "Biological markers of generalized anxiety disorder", Dialogues Clin Neurosci, 19, pp.147~158 (2017)
2. Fındıklı E, "Serum levels of G protein-coupled estrogen receptor 1(GPER1)in drug-naive patients with generalized anxiety disorder", Psychiatry Res, 244, pp.312~316 (2016)
3. Ebru Fındıklı, "The Diagnostic Value of Malondialdehyde, Superoxide Dismutase and Catalase Activity in Drug Naïve, First Episode, Non-Smoker Generalized Anxiety Disorder Patients", Clinical Psychopharmacology and Neuroscience, 16(1), pp.88~94 (2018), 대한정신약물학회[DOI]
4. Meltem Gungor, "Diagnostic Performance of Erythropoietin and Erythropoietin Receptors Levels in Children with Attention Deficit Hyperactivity Disorder", Clinical Psychopharmacology and Neuroscience, 19(3), pp.530~536 (2021), 대한정신약물학회[DOI]
5. Bulut SD, "Serum DHEA-S, testosterone and cortisol levels in female patients with schizophrenia", Endocr Metab Immune Disord Drug Targets, 18, pp.348~354 (2018)
6. Bandelow B, "Biological markers for anxiety disorders, OCD and PTSD : a consensus statement. Part II : neurochemistry, neurophysiology and neurocognition", World J Biol Psychiatry, 18, pp.162~214 (2017)
7. Jelkmann W, "Developments in the therapeutic use of erythropoiesis stimulating agents", Br J Haematol, 141, pp.287~297 (2008)
8. Bernaudin M, "A potential role for erythropoietin in focal permanent cerebral ischemia in mice", J Cereb Blood Flow Metab, 19, pp.643~651 (1999)
9. Sadamoto Y, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery", Biochem Biophys Res Commun, 253, pp.26~32 (1998)
10. Sakanaka M, "In vivo evidence that erythropoietin protects neurons from ischemic damage", Proc Natl Acad Sci U S A, 95, pp.4635~4640 (1998)
11. Lewczuk P, "Survival of hippocampal neurons in culture upon hypoxia : effect of erythropoietin", Neuroreport, 11, pp.3485~3488 (2000)
12. Sirén AL, "Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress", Proc Natl Acad Sci U S A, 98, pp.4044~4049 (2001)
13. Arcasoy MO, "The non-haematopoietic biological effects of erythropoietin", Br J Haematol, 141, pp.14~31 (2008)
14. Juul SE, "Erythropoietin and erythropoietin receptor in the developing human central nervous system", Pediatr Res, 43, pp.40~49 (1998)
15. Morishita E, "Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death", Neuroscience, 76, pp.105~116 (1997)
16. Marti HH, "Erythropoietin and the hypoxic brain", J Exp Biol, 207(Pt 18), pp.3233~3242 (2004)
17. Sasaki R, "Pleiotropic functions and tissue-specific expression of erythropoietin", News Physiol Sci, 16, pp.110~113 (2001)
18. Sharp FR, "HIF1 and oxygen sensing in the brain", Nat Rev Neurosci, 5, pp.437~448 (2004)
19. Hasselblatt M, "The brain erythropoietin system and its potential for therapeutic exploitation in brain disease", J Neurosurg Anesthesiol, 18, pp.132~138 (2006)
20. Ehrenreich H, "Erythropoietin : a candidate compound for neuroprotection in schizophrenia", Mol Psychiatry, 9, pp.42~54 (2004)
21. Ehrenreich H, "Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin", Mol Psychiatry, 12, pp.206~220 (2007)
22. Wüstenberg T, "Recombinant human erythropoietin delays loss of gray matter in chronic schizophrenia", Mol Psychiatry, 16, pp.26~36 (2011)
23. Miskowiak KW, "Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression", Psychopharmacology(Berl), 219, pp.687~698 (2012)
24. Miskowiak KW, "Recombinant human erythropoietin for treating treatment-resistant depression : a double-blind, randomized, placebo-controlled phase 2 trial", Neuropsychopharmacology, 39, pp.1399~1408 (2014)
25. Miskowiak KW, "Neural correlates of improved executive function following erythropoietin treatment in mood disorders", Psychol Med, 46, pp.1679~1691 (2016)
26. 최미연, "Effects of Serotonin on Erythropoietin Expression in Mouse Hippocampus", Experimental Neurobiology, 22(1), pp.45~50 (2013), 한국뇌신경과학회
27. Miskowiak KW, "Recombinant human erythropoietin to target cognitive dysfunction in bipolar disorder : a double-blind, randomized, placebo-controlled phase 2 trial", J Clin Psychiatry, 75, pp.1347~1355 (2014)
28. Miskowiak KW, "Effects of erythropoietin on hippocampal volume and memory in mood disorders", Biol Psychiatry, 78, pp.270~277 (2015)
29. Faul F, "Statistical power analyses using G*Power 3. 1 : tests for correlation and regression analyses", Behav Res Methods, 41, pp.1149~1160 (2009)
30. Hamilton M, "The assessment of anxiety states by rating", Br J Med Psychol, 32, pp.50~55 (1959)
31. Yazici MK, "Hamilton anxiety rating scale : interrater reliabilty and validity study", Turkish J Psychiatry, 9, pp.114~117 (1998)
32. Cahan C, "Diurnal variations in serum erythropoietin levels in healthy subjects and sleep apnea patients", J Appl Physiol(1985), 72, pp.2112~2117 (1992)
33. Camacho A, "Is anxious-depression an inflammatory state?", Med Hypotheses, 81, pp.577~581 (2013)
34. Copeland WE, "Generalized anxiety and C-reactive protein levels : a prospective, longitudinal analysis", Psychol Med, 42, pp.2641~2650 (2012)
35. Vogelzangs N, "Anxiety disorders and inflammation in a large adult cohort", Transl Psychiatry, 3, pp.e249~ (2013)
36. Kemeny ME, "An interdisciplinary research model to investigate psychosocial cofactors in disease : application to HIV-1pathogenesis", Brain Behav Immun, 17(Suppl 1), pp.S62~S72 (2003)
37. Moons WG, "Anger and fear responses to stress have different biological profiles", Brain Behav Immun, 24, pp.215~219 (2010)
38. O’Donovan A, "Clinical anxiety, cortisol and interleukin-6 : evidence for specificity in emotion-biology relationships", Brain Behav Immun, 24, pp.1074~1077 (2010)
39. Steiner J, "Bridging the gap between the immune and glutamate hypotheses of schizophrenia and major depression : potential role of glial NMDA receptor modulators and impaired bloodbrain barrier integrity", World J Biol Psychiatry, 13, pp.482~492 (2012)
40. Sosa I, "Recombinant human erythropoietin as a neuroprotective therapy in brain ischemia", Biotecnol Apl, 25, pp.223~229 (2008)
41. Sirén AL, "Erythropoietin and erythropoietin receptor in human ischemic", hypoxic brain, 2001, pp.101, 271~276
42. Sirén AL, "Global brain atrophy after unilateral parietal lesion and its prevention by erythropoietin", Brain, 129(Pt 2), pp.480~489 (2006)
43. Villa P, "Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis", J Exp Med, 198, pp.971~975 (2003)
44. Yu YP, "Intranasal recombinant human erythropoietin protects rats against focal cerebral ischemia", Neurosci Lett, 387, pp.5~10 (2005)
45. Zhang F, "Erythropoietin protects CA1 neurons against global cerebral ischemia in rat : potential signaling mechanisms", J Neurosci Res, 83, pp.1241~1251 (2006)
46. Taylor R, "Interpretation of the correlation coefficient : a basic review", J Diagn Med Sonography, 6, pp.35~39 (1990)
47. Kim JW, "Diagnostic utility of quantitative EEG in un-medicated schizophrenia", Neurosci Lett, 589, pp.126~131 (2015)
48. Bulut M, "Reduced PON1 enzymatic activity and increased lipid hydroperoxide levels that point out oxidative stress in generalized anxiety disorder", J Affect Disord, 150, pp.829~833 (2013)

관련 논문AI추천